Adam J. Gadzinski, MD, MS, on the Research Coming Out of SUO This Year

Video

Gadzinski spoke about the most exciting aspect of the research coming out of the 21st Annual Meeting of the Society of Urologic Oncology (SUO).

In an interview with CancerNetwork®, Adam J. Gadzinski, MD, MS, urologic oncology fellow and acting clinical instructor in the Department of Urology at the University of Washington, discussed what is most exciting about the research being presented this year at the 21st Annual Meeting of the Society of Urologic Oncology (SUO).

Transcription:

I think a lot of the discussions have been around some of the new systemic treatments in prostate cancer and the genomic mutations in prostate cancer and how those are just now starting to guide our therapies for advanced prostate cancer. That's a very exciting place.

In the last 10 years, there's been numerous advances in men with metastatic prostate cancer. For decades, it was hormone suppression, whether that was achieved with shots or removing the testicles, and that was it. And now we're kind of an embarrassment of riches, and we keep getting more and now we're finding which specific ones work best for which specific patients with a subtype of cancer. So now we can accurately say we're getting to the personalized medicine that we've been talking a lot about for the last 20 years. We're finally getting there now.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content